Abbott Laboratories Offering Investors Expanded Late-Stage Drug Pipeline Seeking Alpha With the purchase came multiple-sclerosis drug daclizumab and late-stage multiple-myeloma treatment elotuzumab, which have both given encouraging Phase II data so far. Abbott is now looking forward to clinical data from these and other drugs as the ... |
